Core Insights - The company reported a revenue of approximately HKD 323 million for the six months ending September 30, 2025, representing a year-on-year decrease of 6.93% [1] - The profit attributable to the parent company was HKD 2.772 million, a significant decline of 88.3% compared to HKD 23.701 million in the same period last year [1] - Earnings per share were reported at HKD 0.025 [1] Revenue Performance - The decrease in revenue is primarily attributed to weakened sales performance in traditional Chinese medicine, Western medicine, and health food products [1]

Financial Performance - Revenue for the six months ended September 30, 2025, was HKD 322.8 million, a decrease of 6.9% compared to HKD 346.8 million in the same period of 2024[2] - Gross profit for the same period was HKD 165.3 million, down 9.2% from HKD 182.0 million year-on-year[2] - Profit attributable to equity holders of the parent was HKD 2.8 million, representing an 88.2% decline from HKD 23.7 million in the previous year[2] - Basic and diluted earnings per share decreased to HKD 0.25 from HKD 2.10, a drop of HKD 1.85[2] - The total comprehensive income for the period was HKD 1.91 million, a significant decrease from HKD 24.00 million in the previous year[5] - The group recorded a total net income of HKD 2,799,000 for the period, significantly lower than HKD 23,742,000 in the previous year, marking a decline of 88.2%[15] - The adjusted profit before tax for the group was HKD 2,539,000, compared to HKD 25,152,000 in the prior year, indicating a decrease of 89.9%[15] Revenue Breakdown - The Chinese medicine segment generated revenue of HKD 292,825,000, down from HKD 306,351,000, reflecting a decline of 4.4%[15] - The Western medicine segment's revenue decreased to HKD 28,635,000 from HKD 38,461,000, representing a decline of 25.5%[15] - The property investment segment reported revenue of HKD 1,357,000, down from HKD 2,031,000, a decrease of 33.2%[16] - For the six months ended September 30, 2025, total revenue was HKD 321,460,000, with the Chinese medicine segment contributing HKD 292,825,000 and the Western medicine segment contributing HKD 28,635,000[17] - Revenue from external customers for the Chinese medicine segment was HKD 292,825,000 for the six months ended September 30, 2025, compared to HKD 306,351,000 for the same period in 2024, indicating a decline of 4.4%[19] Assets and Liabilities - Net asset value as of September 30, 2025, was HKD 1,181.5 million, a slight increase of 0.2% from HKD 1,179.6 million[2] - Non-current assets increased from HKD 1,075,411,000 as of March 31, 2025, to HKD 1,114,226,000 as of September 30, 2025, indicating growth in long-term investments[7] - Current assets rose slightly from HKD 614,204,000 to HKD 621,023,000 during the same period, reflecting stable liquidity[7] - Total current liabilities increased from HKD 358,933,000 to HKD 481,833,000, suggesting a rise in short-term obligations[8] - Total interest-bearing liabilities amounted to approximately HKD 301,500,000, with an effective interest rate of about 4.0%, down from 6.1% as of March 31, 2025[51] Cash Flow and Liquidity - Cash and cash equivalents decreased by 8.4% to HKD 121.2 million from HKD 132.3 million[2] - The company reported cash and cash equivalents of HKD 121,169,000 as of September 30, 2025, up from HKD 132,316,000, showing a decrease in cash reserves[7] - The current ratio was approximately 1.3, a decrease from 1.7 as of March 31, 2025, indicating a decline in liquidity[51] Cost Management - Administrative expenses reduced to HKD 53.98 million from HKD 63.44 million, indicating cost control measures[4] - Sales and distribution expenses decreased slightly by approximately HKD 0.2 million or 0.1% to about HKD 131.7 million, offset by increased marketing costs for expanding e-commerce operations[37] - The cost of inventory recognized as an expense was HKD 144,593,000 for the six months ended September 30, 2025, compared to HKD 151,566,000 for the same period in 2024, showing a decrease of 4.6%[22] Strategic Initiatives - The company is committed to ongoing research and development, focusing on new products and technologies to enhance market expansion and competitiveness[9] - The group has adopted revised Hong Kong Financial Reporting Standards, which did not impact the interim financial results due to the nature of the currencies involved[11] - The group continues to focus on resource allocation and performance evaluation across its three operational segments: Chinese medicine, Western medicine, and property investment[12] - The group invested in technology enhancements, successfully implementing a cutting-edge Customer Relationship Management (CRM) system in Hong Kong and mainland China, and introduced an AI-based Traditional Chinese Medicine diagnostic system in flagship stores[43] Market Performance - The group experienced a 4.4% decline in sales from April to September 2025 compared to the same period in 2024, although sales showed signs of recovery during the October National Day holiday[42] - The group’s cross-border e-commerce business achieved a significant growth of approximately 154% during the period, driven by enhanced marketing strategies and expanded distribution channels[42] - The revenue from Western medicine and health food products decreased by 25.5% compared to the same period in 2024, despite the sustained market leadership of Pei Fu Ren cough syrup for fifteen consecutive years[45] Employee and Operational Metrics - The group employed 726 employees as of September 30, 2025, a decrease from 759 employees as of March 31, 2025[61] - The company maintained strict control over trade receivables to minimize credit risk, with overdue balances regularly reviewed by senior management[10] Future Outlook - The group aims to enhance brand competitiveness by providing reliable and diverse products to customers, fostering long-term partnerships with suppliers[62] - The company has established strategic partnerships in the Chinese market, expanding the distribution of its cough syrup through leading chain pharmacies and hospitals, which is expected to drive significant business growth in the coming years[64] - The group is committed to leveraging government support and technological advancements to lead the future development of the traditional Chinese medicine industry in the Greater Bay Area[63]

Core Viewpoint - The company, Bitan Tang (00897), anticipates a significant decrease in profit attributable to shareholders for the six months ending September 30, 2025, projecting it to be no more than approximately HKD 3 million, compared to an estimated profit of about HKD 23.7 million for the six months ending September 30, 2024 [1] Group 1: Profit Forecast - The expected profit decrease is primarily due to a combination of factors, including weak consumer sentiment in the retail market, leading to a revenue decline of approximately 7%, which in turn has resulted in a decrease in gross profit [1] - The net gain from property sales during the reporting period has significantly decreased [1] - The net fair value gain from investment properties has also diminished during the reporting period [1] Group 2: Cost Mitigation - The negative impacts on profit have been partially offset by a reduction in administrative expenses and financing costs during the reporting period [1]

Core Viewpoint - The company, Bitland (00897), anticipates a significant decrease in profit attributable to equity holders for the six months ending September 30, 2025, projecting it to be no more than approximately HKD 3 million, compared to an estimated profit of HKD 23.7 million for the six months ending September 30, 2024 [1] Group 1 - The expected profit decline is primarily due to a combination of factors, including a weak retail market leading to a revenue decrease of approximately 7%, which in turn has resulted in a decline in gross profit [1] - There has been a substantial reduction in net gains from property sales during the reporting period [1] - The net fair value gains from investment properties have also decreased during the reporting period [1] - These negative impacts have been partially offset by a reduction in administrative expenses and financing costs during the reporting period [1]

Core Viewpoint - The company, 位元堂 (00897.HK), anticipates a significant decline in profit for the reporting period, projecting a drop from approximately HKD 23.7 million to no more than HKD 3 million for the profit attributable to the owners of the parent company [1] Summary by Relevant Categories Financial Performance - The expected profit decline is primarily attributed to a weak retail market, resulting in a revenue decrease of about 7%, which has led to a reduction in gross profit [1] - There has been a substantial decrease in net gains from property sales during the reporting period [1] - The net fair value gains from investment properties have also decreased during the reporting period [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED （位 元 堂 藥 業 控 股 有 限 公 司* （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：897） 盈利警告 本公佈由本公司根據上市規則第13.09條及證券及期貨條例第XIVA部項下內 幕消息條文（定 義 見 上 市 規 則）而 作 出。 董 事 會 謹 此 知 會 本 公 司 股 東 及 潛 在 投 資 者，基 於 對 本 集 團 於 報 告 期 間 之 未 經 審 核 綜 合 管 理 賬 目 草 稿 之 初 步 審 閱 及 董 事 會 目 前 可 得 之 資 料，本 集 團 預 期將錄得於相應期間母公司擁有人應佔溢利約23,700,000港元減少至於報告 期間母公司擁有人應佔溢利不多於約3,000,000港 元。 由 於 本 公 司 ...

(於百慕達註冊成立之有限公司) (股份代號 : 897) 董事會會議通告 香港交易及結算所有限公司及香港聯 合交易所有限公司對本通告之 內容概不負責，對其準確性或完整性亦不發表 聲明，並明確表示， 概不對因本通告全部或任何部分內容而 產生或因依賴該等內容而引致 之任何損失承擔任何責任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED (位元堂藥業控股有限公司* ) 於本通告刊發之日，董事會包括執行董事鄧清河先生、鄧蕙敏女士及 羅敏儀女士；及獨立非執行董事李家暉先生、薛永恒教授及陳永光 教授。 * 僅供識別 Wai Yuen Tong Medicine Holdings Limited（位 元 堂 藥 業 控 股 有 限 公 司 * ） （「 本公司 」）董事會（「 董事會 」）謹此公佈，本公司將於二零二五年 十一月二十四日（星期一）舉行董事會 會議，旨在考慮及通過（其中 包括）本公司及其附屬公司截至二零二五年九 月三十日止六個月之 中期業績，以及考慮派發中期股息（如有）。 承董事會命 WAI YUEN TONG MEDICINE HOLDINGS LIMITED (位元 堂藥業 ...

Core Viewpoint - The ownership transfer of Shankai Intelligent has been terminated due to the failure to obtain necessary approvals from the relevant state-owned asset regulatory authorities, raising questions about the underlying reasons for the termination and the company's information disclosure practices [1][2][3]. Group 1: Ownership Transfer Details - Shankai Intelligent announced the termination of the ownership transfer agreement on November 7, citing the lack of approval from state-owned asset regulatory authorities as the reason [2][3]. - The agreement stipulated that the transfer would only take effect upon approval from the shareholders' meeting and the relevant regulatory bodies, which has not been fulfilled [2][3]. - The transfer was initially approved by the local state-owned asset supervision authority, but further approvals from higher-level authorities were required, leading to confusion regarding the approval process [3][4]. Group 2: Key Individuals and Events - Li Yajun, a key figure in the ownership transfer, was detained a month prior to the announcement, which has raised concerns about the legitimacy of the transaction [4][5]. - Li Yajun played a significant role in the transaction, holding a board position at Changjiang Aerospace and being involved with major shareholders [5][6]. - The sudden termination of the ownership transfer followed a report highlighting Li Yajun's situation, indicating a potential link between his legal troubles and the transaction's collapse [1][6]. Group 3: Market Reactions and Stock Performance - Following the announcement of the termination, Shankai Intelligent's stock price experienced a significant drop, with a peak decline of 6% and a closing drop of 1.08% [6]. - Prior to the suspension of trading, the stock had seen a notable increase of 38% over 13 trading days, raising suspicions among investors regarding the timing of the price movements [7][8]. - New shareholders emerged just before the stock price surge, but they disappeared from the top ten shareholders list in the subsequent quarterly report, indicating potential volatility in shareholder composition [8][9].

Core Viewpoint - The ownership transfer plan of Shankai Intelligent (300897) is facing difficulties due to the recent issues surrounding key figure Li Yajun, who is linked to the buyer, Hubei Changjiang Aerospace Technology Investment Co., Ltd. [1][6] Group 1: Ownership Transfer Plan - In July 2025, Shankai Intelligent announced a plan to transfer control to Hubei Changjiang, which would make the Wuhan New District State-owned Assets Supervision and Administration Commission the new controlling entity [1][2]. - The transfer agreement states that Changjiang Aerospace will acquire a 19.70% stake at a price of 20.7 yuan per share [2][3]. - Li Yajun, chairman of Shanghai Linxin Investment Management Co., is a significant figure in this transaction, holding key positions in both Linxin Investment and Changjiang Aerospace [5][6]. Group 2: Li Yajun's Situation - Li Yajun has reportedly been detained for over a month, which has not been disclosed by Shankai Intelligent [1][9]. - His absence has been noted in another company, Chongqing Road and Bridge, where he is unable to fulfill his duties as general manager due to personal reasons [7][10]. - The lack of updates regarding Li Yajun's status raises concerns about the stability of the ownership transfer plan [10]. Group 3: Financial Performance - Shankai Intelligent's financial performance has been declining, with a 28.96% year-on-year drop in revenue to 236 million yuan in the first half of 2025, and a 48.36% decrease in net profit [11][12]. - The company's third-quarter report shows a 22.56% decline in revenue to 380 million yuan and a 59.34% drop in net profit [12]. - The company's accounts receivable reached 372 million yuan, which is 457% of the net profit, indicating potential issues with profit quality [12]. Group 4: Market Concerns - Prior to the suspension of trading, Shankai Intelligent's stock price experienced significant fluctuations, rising 38% over 13 trading days [13][14]. - New shareholders appeared in the top ten list just before the stock price surge, raising suspicions of insider trading [13][14]. - The combination of declining performance, unusual stock activity, and the high premium paid by state-owned entities for the acquisition has led to skepticism about the transaction [14].

致：香港交易及結算所有限公司 公司名稱: Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司) 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00897 | 說明 | 位元堂 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | 本月底法定/註冊股本總額： HKD 600,000,000 FF301 股份發行人 ...